Note 15 - Segments

9 Months Ended

Sep. 30, 2024

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

NOTE 15 SEGMENTS

We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations through BioReference. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:

	For the three months ended September 30,						For the nine months ended September 30,
(In thousands)	2024			2023			2024			2023
Revenue from services:
Pharmaceutical	$	—		$	—		$	—		$	—
Diagnostics		121,271			131,679			377,557			391,100
Corporate		—			—			—			—
	$	121,271		$	131,679		$	377,557		$	391,100
Revenue from products:
Pharmaceutical	$	39,143		$	40,670		$	117,675		$	124,553
Diagnostics		—			—			—			—
Corporate		—			—			—			—
	$	39,143		$	40,670		$	117,675		$	124,553
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	13,218		$	6,246		$	34,272		$	165,938
Diagnostics		—			—			—			—
Corporate		—			—			—			—
	$	13,218		$	6,246		$	34,272		$	165,938
Operating income (loss):
Pharmaceutical	$	(32,196	)	$	(25,375	)	$	(84,697	)	$	57,210
Diagnostics		58,541			(29,081	)		(2,443	)		(113,344	)
Corporate		(12,129	)		(9,951	)		(31,786	)		(31,841	)
	$	14,216		$	(64,407	)	$	(118,926	)	$	(87,975	)
Depreciation and amortization:
Pharmaceutical	$	18,043		$	17,807		$	53,899		$	53,649
Diagnostics		6,120			8,376			20,238			25,666
Corporate		—			—			—			—
	$	24,163		$	26,183		$	74,137		$	79,315
Loss from investment in investees:
Pharmaceutical	$	(3	)	$	(20	)	$	(7	)	$	(99	)
Diagnostics		—			—			—			—
Corporate		—			—			—			—
	$	(3	)	$	(20	)	$	(7	)	$	(99	)
Revenues:
United States	$	132,663		$	139,043		$	410,422		$	462,987
Ireland		11,514			8,654			30,579			121,249
Chile		16,576			16,932			49,067			52,427
Spain		6,297			4,349			17,828			16,427
Israel		196			3,155			797			9,388
Mexico		5,630			5,897			18,621			17,447
Other		756			565			2,190			1,666
	$	173,632		$	178,595		$	529,504		$	681,591

	September 30,		December 31,
(In thousands)	2024		2023
Assets:
Pharmaceutical	$	1,271,781	$	1,331,764
Diagnostics		517,871		630,753
Corporate		466,451		49,181
	$	2,256,103	$	2,011,698
Goodwill:
Pharmaceutical	$	316,161	$	315,235
Diagnostics		219,707		283,025
	$	535,868	$	598,260

No customer represented more than 10% of our total consolidated revenue for the nine months ended September 30, 2024 and 2023. As of September 30, 2024 and December 31, 2023, no customer represented more than 10% of our accounts receivable balance.